ABHD11 Inhibitors

The class of 'ABHD11 Inhibitors' encompasses a variety of chemical compounds that indirectly affect the function of the ABHD11 protein. These inhibitors do not directly target the ABHD11 protein but rather influence cellular pathways or processes that ABHD11 is a part of or interacts with. For instance, compounds like histone deacetylase inhibitors (e.g., Trichostatin A) and DNA methyltransferase inhibitors (e.g., 5-Azacytidine) can alter gene expression patterns, which may include the downregulation of ABHD11 expression. Similarly, proteasome inhibitors (e.g., MG132) can prevent the degradation of proteins, indirectly affecting the turnover and steady-state levels of ABHD11 within the cell.

Modulators of lipid signaling, such as FAAH inhibitors (e.g., PF-3845 and URB597), and inhibitors targeting other ABHD proteins (e.g., WWL70 for ABHD6 and CAY10499 for ABHD12), can perturb lipid signaling networks. These alterations can have downstream effects on the functions of proteins within these networks, including ABHD11. Compounds like GW4869, which inhibits neutral sphingomyelinase, and Manumycin A, targeting Ras farnesyltransferase, can exert influence over sphingolipid metabolism and Ras signaling pathways, respectively, thereby modulating ABHD11's activity indirectly. Inhibitors of key signaling kinases such as LY294002, a PI3K inhibitor, and SP600125, a JNK inhibitor, can impact the Akt signaling pathway and AP-1 transcription factor activity, which might result in changes to ABHD11 expression or function.